Guangzhou, China – 17 Sep 2026 – The Guangdong Drug Exchange Center launched the viewing and confirmation of linkage price information for some listed drugs (Batch 20260917), covering provincial centralized procurement (VBP) winning products priced above other provinces’ winning prices, same‑enterprise products under price‑differential rules, and “Four‑Same” drugs (same generic name, brand, dosage form and specification) listed above the national lowest listing price — with a confirmation window closing at 17:00 on 20 September 2026 and automatic linkage price adjustment, disqualification or delisting for non‑responsive enterprises.
Notice Snapshot
| Item | Detail |
|---|---|
| Authority | Guangdong Drug Exchange Center (Guangdong Province, China) |
| Action | Linkage price viewing & confirmation for selected listed drugs |
| Batch | 20260917 |
| Product Scope | ① VBP winners (incl. limited‑volume winners) whose provincial winning price exceeds other provinces’; ② same‑enterprise winners under price‑differential/comparison rules; ③ “Four‑Same” drugs listed above the national lowest listing price (as of 16 Sep 2026; details in system) |
| Confirmation Window | Immediate – 20 Sep 2026, 17:00 |
| Platform | Guangdong Drug & Medical Consumables Procurement Subsystem (CA certificate login) |
| Policy Basis | National drug price governance requirements |
Confirmation Paths & Consequences
- Viewing Path (VBP winners above other provinces’ prices): Log in with CA certificate → “Drug Centralized Procurement Management – Drug Price Management – Drug Price Publication – Provincial VBP Winning Product Linkage Price Information Viewing (Batch 20260917).”
- Confirmation Path (price‑differential winners & “Four‑Same” drugs): Log in with CA certificate → “Drug Price Confirmation – Provincial VBP Winning Products and ‘Four‑Same’ Drug Linkage Price Confirmation (Batch 20260917).”
- Appeal Mechanism: Enterprises disputing prices must upload appeal materials stamped with the company seal on every page via the designated appeal attachment path within the window; late objections or missing evidence will in principle not be accepted.
- VBP Winners Above Other Provinces: No objection, or appeal rejected → winning price adjusted downward via linkage automatically.
- Price‑Differential Winners: Confirm within deadline → linkage adjustment applies; refuse confirmation with appeal rejected, or miss the deadline → winning qualification cancelled per procurement documents.
- “Four‑Same” Listed Drugs: Confirm within deadline → unified price adjustment across the province’s three platforms; refuse with appeal rejected, or miss the deadline → listing revoked, with relisting only via a fresh application through the standard listing process.
- Ongoing Self‑Check Duty: Enterprises must monitor prices in other provinces and submit price adjustment applications through the subsystem within 30 days of any new lower winning or listing price taking effect elsewhere.
Sector Background
- Linkage Price Mechanism: Cross‑province price linkage forces listed and VBP‑winning prices toward the national lowest benchmark, a core pillar of China’s drug price governance that compresses inter‑provincial price gaps.
- “Four‑Same” Targeting: Identical generic name, brand, dosage form and specification — the tightest comparability standard, closing arbitrage where the same product holds different prices across platforms.
- Three‑Platform Unification: Confirmed “Four‑Same” adjustments apply uniformly across Guangdong’s three procurement platforms, eliminating within‑province price fragmentation.
- Contact Channels: Online customer service via the Guangdong Drug Exchange Center website; hotlines 020‑87709875 / 020‑38036197 (weekdays 8:30–12:00, 14:00–17:30).
Market Impact & Outlook
- Immediate Revenue Risk: For affected products, linkage adjustment means direct price cuts in Guangdong, one of China’s largest pharmaceutical markets — material for enterprises with concentrated provincial exposure.
- Compliance Deadline Pressure: The four‑day window (closing 20 Sep, 17:00) makes timely CA‑certificate login and price confirmation operationally critical; missed deadlines trigger disqualification or delisting without further recourse.
- National Price Discipline: The 30‑day self‑reporting duty institutionalizes continuous downward price surveillance — enterprises should embed cross‑province price monitoring into routine market‑access operations.
- Strategic Considerations: Companies facing steep linkage cuts must weigh confirmation against withdrawal economics per product, factoring in relisting costs and the risk of setting new national price precedents.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding linkage price adjustments, appeals outcomes and potential disqualification or delisting of listed drugs in Guangdong. Actual price changes depend on enterprise confirmations, appeal adjudications and system data as of the batch cut‑off date, and may differ materially from current expectations.-China Health Reform Pulse
Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=2100576933975691264